Tris Pharma
Peter joined Tris Pharma in April 2010 and leads our licensing and M&A initiatives. Peter brings to Tris a diverse background and an analytical approach steeped in pharmaceutical markets. He is a pharmacist by training and holds an MBA in finance from Rutgers University. After business school, he joined a boutique strategic management consulting firm where he spent six-plus years, serving as Vice President for the last three years. His clients included leading pharmaceutical firms such as Pfizer and Novartis, drug distribution companies, and health system firms. Peter then spent six years at Kos Pharmaceuticals, serving for the last two years as Executive Director of Corporate Development and Business Planning prior to Kos’ acquisition by Abbott Labs.
This person is not in any offices
Tris Pharma
1 followers
Tris Pharma, Inc. is one of the top five privately-owned specialty pharmaceutical companies in the U.S. with a focus on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies.